JP2004538477A5 - - Google Patents

Download PDF

Info

Publication number
JP2004538477A5
JP2004538477A5 JP2003520382A JP2003520382A JP2004538477A5 JP 2004538477 A5 JP2004538477 A5 JP 2004538477A5 JP 2003520382 A JP2003520382 A JP 2003520382A JP 2003520382 A JP2003520382 A JP 2003520382A JP 2004538477 A5 JP2004538477 A5 JP 2004538477A5
Authority
JP
Japan
Prior art keywords
patient
level
antibody
time interval
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003520382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004538477A (ja
JP4511830B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/026321 external-priority patent/WO2003015617A2/en
Publication of JP2004538477A publication Critical patent/JP2004538477A/ja
Publication of JP2004538477A5 publication Critical patent/JP2004538477A5/ja
Application granted granted Critical
Publication of JP4511830B2 publication Critical patent/JP4511830B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003520382A 2001-08-17 2002-08-16 アルツハイマー病のアッセイ方法 Expired - Lifetime JP4511830B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31322101P 2001-08-17 2001-08-17
US31322401P 2001-08-17 2001-08-17
US33498701P 2001-10-23 2001-10-23
PCT/US2002/026321 WO2003015617A2 (en) 2001-08-17 2002-08-16 Assay method for alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009208372A Division JP5162553B2 (ja) 2001-08-17 2009-09-09 アルツハイマー病のアッセイ方法

Publications (3)

Publication Number Publication Date
JP2004538477A JP2004538477A (ja) 2004-12-24
JP2004538477A5 true JP2004538477A5 (enExample) 2006-01-05
JP4511830B2 JP4511830B2 (ja) 2010-07-28

Family

ID=27405654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003520382A Expired - Lifetime JP4511830B2 (ja) 2001-08-17 2002-08-16 アルツハイマー病のアッセイ方法
JP2009208372A Expired - Lifetime JP5162553B2 (ja) 2001-08-17 2009-09-09 アルツハイマー病のアッセイ方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009208372A Expired - Lifetime JP5162553B2 (ja) 2001-08-17 2009-09-09 アルツハイマー病のアッセイ方法

Country Status (10)

Country Link
EP (1) EP1416965B8 (enExample)
JP (2) JP4511830B2 (enExample)
AT (1) ATE381346T1 (enExample)
CA (1) CA2457145C (enExample)
CY (1) CY1107901T1 (enExample)
DE (1) DE60224200T2 (enExample)
DK (1) DK1416965T3 (enExample)
ES (1) ES2295401T3 (enExample)
PT (1) PT1416965E (enExample)
WO (1) WO2003015617A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151378A0 (en) 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
US7771722B2 (en) 2001-08-17 2010-08-10 Eli Lilly And Company Assay method for alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7575747B2 (en) 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
EP1480041A1 (en) * 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CA2675847C (en) 2007-01-18 2014-12-30 Eli Lilly And Company Pegylated a.beta. fab
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2010093001A1 (ja) * 2009-02-13 2010-08-19 国立大学法人大阪大学 アルツハイマー病の診断方法および診断薬
KR101531949B1 (ko) 2009-12-11 2015-06-26 아라클론 바이오테크, 에스.엘. 아밀로이드 베타 펩티드의 개선된 검출 방법 및 시약
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
IL245703B (en) * 2013-11-20 2022-07-01 Univ Iowa Res Found Methods and compositions for treating amyloid deposits
CN109187981A (zh) * 2018-08-01 2019-01-11 万东山 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用
KR102496845B1 (ko) * 2018-08-08 2023-02-08 서울대학교산학협력단 진단 지표로서 베타-아밀로이드 수준과 함께 혈장 타우 수준을 사용하는 알츠하이머병의 진단 및 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298436B1 (en) * 1992-10-26 2010-07-14 Elan Pharmaceuticals, Inc. Methods for the identification of Beta-amyloid peptide (BAP) release inhibitor compounds
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6730778B2 (en) * 1997-12-19 2004-05-04 Pharmacia And Upjohn Company Human sel-10 polypeptides and polynucleotides that encode them
IL151378A0 (en) * 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide

Similar Documents

Publication Publication Date Title
Jusko et al. Plasma and tissue protein binding of drugs in pharmacokinetics
JP2002533680A5 (enExample)
JP2006516116A5 (enExample)
JP2004532817A5 (enExample)
KR101155294B1 (ko) 면역특이적으로 BLyS에 결합하는 항체
JP2018503618A5 (enExample)
EA200500715A1 (ru) Новые лекарственные средства для лечения хронического обструктивного заболевания лёгких
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
JP2019517473A5 (enExample)
JP2009173684A (ja) 腎臓結石疾患の予防のための希土類化合物の使用
EP1408333A3 (en) Diagnosis and treatment of Alzheimer's disease
JP2022095754A (ja) ループス腎炎の治療のための改善されたプロトコル
JP2021534195A5 (enExample)
CA2457145A1 (en) Assay method for alzheimer's disease
CN112312917A (zh) 用于治疗幻觉及其相关病症的方法和组合物
JP6725515B2 (ja) 小分子を用いた鉄欠乏生物における生理機能の回復
US20180110785A1 (en) Methods and compositions for ameliorating symptoms associated with chromosomal abnormalities
JP2011523405A5 (enExample)
JP2006505536A5 (enExample)
WO2004094648A3 (en) Methods of treating diseases responsive to induction of apoptosis and screening assays
Zhu et al. Detection of IgE antibodies specific for 1-phenyl-2, 3-dimethyl-3-pyrazoline-5-one by RAST: a serological diagnostic method for sensitivity to pyrazoline drugs
Sha et al. In vivo electroporation of a new gene vaccine encoding ten repeats of Aβ3-10 prevents brain Aβ deposition and delays cognitive impairment in young Tg-APPswe/PSEN1dE9 mice
ATE498403T1 (de) Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
EP3137094A1 (en) Treatment and prevention of alzheimer's disease (ad)
Huang et al. Case report: atenolol overdose successfully treated with hemodialysis